Targeting CCL11 in the treatment of ovarian cancer.
BACKGROUND
The chemokine network, comprised of mediators of inflammation, has been implicated in the development of a number of human cancers. The eosinophil chemoattractant CCL11 was recently shown to play a role in the development of ovarian cancer. Here we review findings regarding CCL11 and discuss its use as a target in the treatment of ovarian cancer.


METHODS
We review published findings related to the physiological actions of CCL11, its tumourigenic effects, the chemokine network and inflammatory response present in ovarian cancer, and the current state of therapeutics targeting CCL11 and its receptors. Findings published within the last 10 years receive particular attention.


RESULTS
An overview of the emerging role of the chemokine network in malignancy and a review of the role of CCL11 in ovarian tumourigenesis. The reader will be presented with a description of the unique aspects of CCL11 action and the inflammatory environment in the setting of ovarian malignancy that make this chemokine an attractive target for intervention.


CONCLUSIONS
Targeting CCL11 and its receptors through the use of monoclonal antibodies and small-molecule inhibitors may represent a beneficial new avenue of ovarian cancer treatment.
Nolen
Brian M
BM
University of Pittsburgh, Cancer Institute, Hillman Cancer Center, Suite 1.19d, 5117 Centre Avenue, Pittsburgh, PA 15213, USA.
Lokshin
Anna E
AE
D002465:Cell Movement; D054413:Chemokine CCL11 / Q000037:antagonists & inhibitors* / Q000502:physiology; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000502:physiology; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000209:etiology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000209:etiology
D054413:Chemokine CCL11